Loriot, Y., Siefker-Radtke, A. O., Friedlander, T. W., Necchi, A., Wei, A. Z., Sridhar, S. S., Garmezy, B., Arroyo, S., Gartside, E., Liu, J., Campbell, C., Bader, J., Petrylak, D. P. (2025). A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC; Duravelo-2).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps4619